Form 13-F position report

ZEVRA THERAPEUTICS INC Put options

Reported by SABBY MANAGEMENT LLC

ZVRA CUSIP 488445956 Manager CIK 0001535610

Reported 864 underlying shares controlled, up 437 (102.3%) from the prior quarter.

Reported value -38.6%; share count 102.3% vs. the prior quarter.

Added
% of reported 13F value 4.17% This manager · Q3 2026
Underlying shares 864 Quarter-end amount reported
Reported notional value $375,840 Underlying-share value; not option premium
Consecutive quarters held 8 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 2536000
2022-03-31 1836000
2022-06-30 1708000
2022-09-30 2583000
2022-12-31 411264
2023-03-31 0
2024-12-31 135942
2025-03-31 344800
2025-06-30 93386
2025-09-30 310977
2025-12-31 292992
2026-03-31 316880
2026-06-30 612318
2026-09-30 375840

Quarterly position history

How this manager's reported quarter-end position changed over time.

14 quarters
Quarterly reported position history for ZEVRA THERAPEUTICS INC held by SABBY MANAGEMENT LLC.
Quarter Activity Underlying shares Change % of reported 13F Reported notional value Filed Source filing
Q3 2026 Added 864 +437 (102.3%) 4.17% $375,840 2026-11-13
Q2 2026 Added 427 +87 (25.6%) 0.55% $612,318 2026-08-14
Q1 2026 Added 340 +13 (4.0%) 0.7% $316,880 2026-05-15
Q4 2025 Unchanged 327 0 (0.0%) 0.42% $292,992 2026-02-17
Q3 2025 Added 327 +221 (208.5%) 0.36% $310,977 2025-11-14
Q2 2025 Reduced 106 -650 (-86.0%) 0.17% $93,386 2025-08-14
Q1 2025 Added 756 +593 (363.8%) 1.01% $344,800 2025-05-15
Q4 2024 New 163 +163 (0.0%) 0.18% $135,942 2025-02-14
Q1 2023 Reduced 0 -896 (-100.0%) 0 $0 2023-05-15
Q4 2022 Reduced 896 -3,244 (-78.4%) 0.36% $411,264 2023-02-14
Q3 2022 Added 4,140 +310 (8.1%) 3.26% $2,583,000 2022-11-14
Q2 2022 Added 3,830 +179 (4.9%) 1.16% $1,708,000 2022-08-15
Q1 2022 Added 3,651 +785 (27.4%) 0.27% $1,836,000 2022-05-16
Q4 2021 Reduced 2,866 -46 (-1.6%) 0.37% $2,536,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

4 managers reported ZEVRA THERAPEUTICS INC for Q3 2026.

Managers reporting ZEVRA THERAPEUTICS INC in Q3 2026.
Manager Activity Underlying shares Change % of reported 13F Reported notional value Tenure
IMC-Chicago LLC Added 68,800 +56,400 < 0.01% $754,736 2 qtrs
GROUP ONE TRADING L P Added 43,200 +21,900 < 0.01% $473,904 23 qtrs
SIMPLEX TRADING LLC Added 35,300 +13,000 < 0.01% $387,241 23 qtrs
SABBY MANAGEMENT LLC This report Added 864 +437 4.17% $375,840 8 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 13, 2026
Filing type
13F-HR
Position type
Put options

Voting authority reported

Sole
0
Shared
864
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.